Plain-English translation of NCT07042802 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new drug called LBL-024 in combination with an existing chemotherapy called paclitaxel for patients with platinum-resistant ovarian cancer—meaning their cancer has stopped responding to platinum-based treatments they received earlier. The study has two parts: first, researchers will give a small group of patients the new medication to make sure it's safe and tolerable, and then they'll expand to a larger group where some patients receive the combination treatment and others receive chemotherapy alone. The goal is to see if adding this medication to chemotherapy helps patients live longer and better.
Ovarian cancer that becomes resistant to platinum treatments is very difficult to manage, and patients urgently need new options. This trial is designed to find out whether this medication can improve outcomes when combined with existing chemotherapy.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive either the new medication plus chemotherapy, or chemotherapy alone, depending on which group you're assigned to. The trial has two phases: in the first phase, a small group of patients will start treatment so researchers can monitor safety; if all goes well, the study expands to enroll more patients. Treatment cycles last 21 days, and you'll receive your medications by intravenous infusion (through an IV). You'll need to attend regular clinic visits for blood tests, imaging scans, and check-ups to track how you're responding and monitor for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China